Most Popular

Brean Capital Weighs In on Skyworks Solutions Inc (SWKS) Following Preliminary Q3:15 Results and PMC-Sierra Acquisition

In a research report released today, Brean Capital analyst Mike Burton reiterated a Buy rating on shares of Skyworks Solutions Inc (NASDAQ:SWKS), while reducing …

Canaccord Slashes Price Target For Exact Sciences Corporation (EXAS) As Risk/Reward Looks Less Compelling

In a research report issued Wednesday, Canaccord analyst Mark Massaro reiterated a Buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS), while reducing the …

Canaccord Reiterates Buy on Pandora Media Inc (P) on Back of Ticketfly Acquisition

In a research report issued today, Canaccord analyst Michael Graham reiterated a Buy rating on shares of Pandora Media Inc (NYSE:P) with a price …

PepsiCo, Inc. (PEP): Third Quarter Results and Suspicious Share Repurchases

PepsiCo, Inc. (NYSE:PEP) released its 3rd quarter results yesterday.

Analysts Weigh In on Sarepta Therapeutics Inc Following Additional Data on Eteplirsen

Sarepta Therapeutics Inc (NASDAQ:SRPT) shared additional data from the Phase 2b program of Eteplirsen on October 1. The data features details about safety …

BTIG Pounds The Table On Palo Alto Networks Inc (PANW)

BTIG analyst Joel Fishbein was out pounding the table on Palo Alto Networks Inc (NYSE:PANW) Monday, reiterating a Buy rating and price target of $210, which implies an upside …

Illumina, Inc. (ILMN) Announces Preliminary Revenue for Third Quarter of Fiscal Year 2015

Illumina, Inc. (NASDAQ:ILMN) announced estimated third quarter revenue of approximately $550 million, a 14% increase compared to $481 million in the third quarter of 2014 and …

Maxim Weighs In On Bluebird Bio Inc Following Investors Meeting With Management

Maxim’s healthcare analyst Jason McCarthy weighed in today with an optimistic view on bluebird bio Inc  (NASDAQ:BLUE), after spending an evening with bluebird management and clients, …

Roth Capital Raises Price Target for AcelRx Pharmaceuticals Inc (ACRXׁ) Following Analyst Day

In a research report issued today, Roth Capital analyst Michael Higgins reiterated a Buy rating on shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) while raising the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts